OBJECTIVE: We recently described anti-atherogenic properties of the dual domain peptide Ac-hE18A-NH(2) derived by covalently linking the heparin binding domain 141-150 of apoE to 18A, a class A amphipathic helical peptide. In this paper we have compared the properties of Ac-hE18A-NH(2) with the non-heparin binding 151-160 region of apoE linked to 18A (Ac-nhE18A-NH(2)). METHODS AND RESULTS: Both peptides were highly helical in solution and in association with lipids. Ac-hE18A-NH(2) and not Ac-nhE18A-NH(2) enhanced uptake of low density lipoprotein (LDL) in HepG2 cells. While Ac-hE18A-NH(2) retarded the electrophoretic mobility of LDL, Ac-nhE18A-NH(2) slightly enhanced mobility. Ac-hE18A-NH(2) reduced monocyte association with endothelial cells, while Ac-nhE18A-NH(2) increased it. Ac-hE18A-NH(2) also reduced lipid hydroperoxide content of LDL while Ac-nhE18A-NH(2) increased it. A single administration of Ac-hE18A-NH(2) (100 μg/mouse) into apoE null mice dramatically reduced cholesterol (from 600 mg/dL to 180 mg/dL at 5 min and to 60 mg/dL at 5h) while Ac-nhE18A-NH(2) had no effect. Administration (100 μg/mouse/day, three days a week) into apoE null mice for six weeks showed Ac-hE18A-NH(2) group having a moderate aortic sinus lesion reduction compared with the control group (-15.1%), while the Ac-nhE18A-NH(2) administered group had increased lesion area (+33.0% vs controls and 36.1% vs Ac-hE18A-NH(2)). Plasma from mice administered Ac-hE18A-NH(2) for six weeks showed a significant reduction in plasma cholesterol and triglyceride levels and increase in paraoxonase-1 (PON-1) activity compared to controls, while Ac-nhE18A-NH(2) caused no change in plasma cholesterol and decreased PON-1 activity. CONCLUSION: It is proposed that Ac-hE18A-NH(2) reduced lesion progression in apoE null mice due to its anti-inflammatory and lipoprotein clearing properties, while Ac-nhE18A-NH(2) exhibited pro-atherogenic effects.
OBJECTIVE: We recently described anti-atherogenic properties of the dual domain peptide Ac-hE18A-NH(2) derived by covalently linking the heparin binding domain 141-150 of apoE to 18A, a class A amphipathic helical peptide. In this paper we have compared the properties of Ac-hE18A-NH(2) with the non-heparin binding 151-160 region of apoE linked to 18A (Ac-nhE18A-NH(2)). METHODS AND RESULTS: Both peptides were highly helical in solution and in association with lipids. Ac-hE18A-NH(2) and not Ac-nhE18A-NH(2) enhanced uptake of low density lipoprotein (LDL) in HepG2 cells. While Ac-hE18A-NH(2) retarded the electrophoretic mobility of LDL, Ac-nhE18A-NH(2) slightly enhanced mobility. Ac-hE18A-NH(2) reduced monocyte association with endothelial cells, while Ac-nhE18A-NH(2) increased it. Ac-hE18A-NH(2) also reduced lipid hydroperoxide content of LDL while Ac-nhE18A-NH(2) increased it. A single administration of Ac-hE18A-NH(2) (100 μg/mouse) into apoE null mice dramatically reduced cholesterol (from 600 mg/dL to 180 mg/dL at 5 min and to 60 mg/dL at 5h) while Ac-nhE18A-NH(2) had no effect. Administration (100 μg/mouse/day, three days a week) into apoE null mice for six weeks showed Ac-hE18A-NH(2) group having a moderate aortic sinus lesion reduction compared with the control group (-15.1%), while the Ac-nhE18A-NH(2) administered group had increased lesion area (+33.0% vs controls and 36.1% vs Ac-hE18A-NH(2)). Plasma from mice administered Ac-hE18A-NH(2) for six weeks showed a significant reduction in plasma cholesterol and triglyceride levels and increase in paraoxonase-1 (PON-1) activity compared to controls, while Ac-nhE18A-NH(2) caused no change in plasma cholesterol and decreased PON-1 activity. CONCLUSION: It is proposed that Ac-hE18A-NH(2) reduced lesion progression in apoE null mice due to its anti-inflammatory and lipoprotein clearing properties, while Ac-nhE18A-NH(2) exhibited pro-atherogenic effects.
Authors: G M Anantharamaiah; J L Jones; C G Brouillette; C F Schmidt; B H Chung; T A Hughes; A S Bhown; J P Segrest Journal: J Biol Chem Date: 1985-08-25 Impact factor: 5.157
Authors: Geeta Datta; Raquel F Epand; Richard M Epand; Manjula Chaddha; Matthew A Kirksey; David W Garber; Sissel Lund-Katz; Michael C Phillips; Susan Hama; Mohamad Navab; Alan M Fogelman; Mayakonda N Palgunachari; Jere P Segrest; G M Anantharamaiah Journal: J Biol Chem Date: 2004-04-08 Impact factor: 5.157
Authors: A D Cardin; N Hirose; D T Blankenship; R L Jackson; J A Harmony; D A Sparrow; J T Sparrow Journal: Biochem Biophys Res Commun Date: 1986-01-29 Impact factor: 3.575
Authors: Gaurav Nayyar; David W Garber; Mayakonda N Palgunachari; Candyce E Monroe; Tamara D Keenum; Shaila P Handattu; Vinod K Mishra; G M Anantharamaiah Journal: Atherosclerosis Date: 2012-06-23 Impact factor: 5.162
Authors: Gaurav Nayyar; Vinod K Mishra; Shaila P Handattu; Mayakonda N Palgunachari; Ronald Shin; David T McPherson; Champion C S Deivanayagam; David W Garber; Jere P Segrest; G M Anantharamaiah Journal: J Lipid Res Date: 2012-02-29 Impact factor: 5.922
Authors: Oleg F Sharifov; Gaurav Nayyar; Vladimir V Ternovoy; Vinod K Mishra; Silvio H Litovsky; Mayakonda N Palgunachari; David W Garber; G M Anantharamaiah; Himanshu Gupta Journal: Biochem Biophys Res Commun Date: 2013-06-17 Impact factor: 3.575
Authors: Shaila P Handattu; Gaurav Nayyar; David W Garber; Mayakonda N Palgunachari; Candyce E Monroe; Tamara D Keenum; Vinod K Mishra; Geeta Datta; G M Anantharamaiah Journal: Atherosclerosis Date: 2012-11-02 Impact factor: 5.162
Authors: Shaila P Handattu; Candyce E Monroe; Gaurav Nayyar; Mayakonda N Palgunachari; Inga Kadish; Thomas van Groen; G M Anantharamaiah; David W Garber Journal: J Alzheimers Dis Date: 2013 Impact factor: 4.472
Authors: Madelyn S Hanson; Hao Xu; Timothy C Flewelen; Sandra L Holzhauer; Dawn Retherford; Deron W Jones; Anne C Frei; Kirkwood A Pritchard; Cheryl A Hillery; Neil Hogg; Nancy J Wandersee Journal: Am J Physiol Heart Circ Physiol Date: 2012-11-02 Impact factor: 4.733